Browsing Tag
peptide drug conjugates
3 posts
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?
Avacta completes sale of Coris Bioconcept to focus solely on oncology. Find out what this pivot means for its stock, strategy, and pre|CISION® pipeline.